Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post - Takeaways - MDSpire

Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post

  • By

  • Henri Lu

  • Annamaria Kosztin

  • Brian L. Claggett

  • Alberto Foà

  • Maria A. Pabón

  • Akshay S. Desai

  • Pardeep S. Jhund

  • Alasdair D. Henderson

  • Bela Merkely

  • Carolyn S. P. Lam

  • Michele Senni

  • Sanjiv J. Shah

  • Adriaan A. Voors

  • Faiez Zannad

  • Bertram Pitt

  • Flaviana Amarante

  • Riitta Saarinen

  • Yoriko De Sanctis

  • Andrea Glasauer

  • John J. V. McMurray

  • Muthiah Vaduganathan

  • Scott D. Solomon

  • June 1, 2026

  • 0 min

Share

  • 1

    Cardiovascular death remains a significant issue in patients with heart failure with preserved ejection fraction (HFpEF), despite advances in therapies.

  • 2

    Sudden death accounts for 25% to 30% of total deaths in HFpEF trials, surpassing deaths related to pump failure.

  • 3

    Current guidelines do not recommend implantable cardioverter-defibrillators for primary prevention in HFpEF due to insufficient evidence.

  • 4

    The FINEARTS-HF trial analyzed trajectories of functional status, quality of life, and biomarkers preceding sudden death in heart failure patients.

  • 5

    Statistical analyses in the FINEARTS-HF trial utilized linear mixed-effects models to assess longitudinal changes in key parameters over time.

Original Source(s)

Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post

  • by Henri Lu, Annamaria Kosztin, Brian L. Claggett, Alberto Foà, Maria A. Pabón, Akshay S. Desai, Pardeep S. Jhund, Alasdair D. Henderson, Bela Merkely, Carolyn S. P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, Riitta Saarinen, Yoriko De Sanctis, Andrea Glasauer, John J. V. McMurray, Muthiah Vaduganathan, Scott D. Solomon

  • June 1, 2026

Related Content

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity

Latent transition analysis of home-based fluid management during the vulnerable phase in patients with chronic heart failure: impact on symptom burden

Lung ultrasound B-lines, NT-proBNP, and left atrial volume Index for bedside characterization of preserved-ejection-fraction phenotype in acute heart failure: a single-center observational study